Université Libre de Bruxelles - Hôpital Erasme
Welcome,         Profile    Billing    Logout  
 18 Trials 
29 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mhiri, Chokri
NCT03958877 / 2018-003008-38: A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

Active, not recruiting
3
142
Europe, US, RoW
BIIB017 (peginterferon beta-1a), PLEGRIDY, Interferon beta type 1a, Avonex
Biogen
Multiple Sclerosis, Relapsing-Remitting
05/27
05/27
Crenier, Laurent
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
Franchimont, Denis
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Recruiting
2
268
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Crohn's Disease
09/26
07/27
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting
2
207
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Ulcerative Colitis
09/26
08/27
Jiang, Yi
LUCENT-1, NCT03518086 / 2017-003229-14: An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

Checkmark Full data from P3 LUCENT 1 trial for severe ulcerative colitis
Oct 2022 - Oct 2022: Full data from P3 LUCENT 1 trial for severe ulcerative colitis
Checkmark Efficacy and safety data from LUCENT-1 trial for moderately-to-severely active ulcerative colitis
Feb 2022 - Feb 2022: Efficacy and safety data from LUCENT-1 trial for moderately-to-severely active ulcerative colitis
Checkmark From LUCENT 1 trial for ulcerative colitis
More
Completed
3
1281
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828, Placebo
Eli Lilly and Company
Ulcerative Colitis
01/21
05/24
LUCENT-2, NCT03524092 / 2017-003238-96: A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

Checkmark Efficacy and safety data of LUCENT-2 in patients with ulcerative colitis
May 2022 - May 2022: Efficacy and safety data of LUCENT-2 in patients with ulcerative colitis
Checkmark Safety and efficacy data from LUCENT-2 trial for ulcerative colitis
Dec 2021 - Dec 2021: Safety and efficacy data from LUCENT-2 trial for ulcerative colitis
Completed
3
1177
Europe, Canada, Japan, US, RoW
Mirikizumab SC, LY3074828, Mirikizumab IV, Placebo SC
Eli Lilly and Company
Ulcerative Colitis
11/21
12/24
NCT04714190: A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression

Recruiting
3
351
RoW
RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection, Paclitaxel injection, Taxol, Irinotecan Hydrochloride Injection, CAMPTO, Apatinib Mesylate Tablets, Aitan
RemeGen Co., Ltd.
Gastric Cancer, HER2 Overexpressing Gastric Carcinoma
12/24
06/25
MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD
Jan 2024 - Dec 2024: Data from MATINEE trial for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD
Hourglass Jul 2024 - Dec 2024 : Regulatory decision in Japan for COPD
Completed
3
806
Europe, Canada, US, RoW
Placebo, Mepolizumab
GlaxoSmithKline, PPD DEVELOPMENT, LP
Pulmonary Disease, Chronic Obstructive
08/24
08/24
NCT04937387: Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma

Completed
3
359
RoW
FF/VI, FF/UMEC/VI, ELLIPTA
GlaxoSmithKline
Asthma
08/24
08/24
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26
SPH5030-201, NCT06434597: A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.

Recruiting
2
60
RoW
SPH5030
Shanghai Pharmaceuticals Holding Co., Ltd
Biliary Tract or Colorectal Cancer With Her2-positive/Mutated
12/26
12/26
NCT05126719: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

Recruiting
2
238
RoW
MRG003, Capecitabine tablets, Docetaxel injection
Shanghai Miracogen Inc.
Recurrent or Metastatic Nasopharyngeal Carcinoma
10/24
02/25
Borne, Philippe van de
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
YILMAZ, Hasan Guney
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting
3
612
Europe, Canada, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26
ABTECT, NCT05535946: - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
HORIZON, NCT05583344 / 2022-002538-14: Phase 2b Study of GSK4532990 in Adults With NASH

Active, not recruiting
2
271
Europe, Canada, Japan, US, RoW
GSK4532990, Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
12/25
03/26
Eun, Chang Soo
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26
ZHENG, Chang Qing
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
SZALAI, LASZLO
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26
Donets, Dmytro
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26
Cremer, Anneline
CARUC-ASA, NCT05992142: ChAracterizing the Remission Status in Patients With Ulcerative Colitis Treated by 5-ASA

Completed
4
200
Europe
5-ASA
Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW, Ferring Pharmaceuticals
Ulcerative Colitis
02/24
02/24
AMARETTO, NCT06113913: Subcutaneous Infliximab After A Previous Intravenous Dose Optimization

Recruiting
4
275
Europe
Infliximab
Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW, Celltrion
Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
05/26
11/26
Pradhan, Rajesh
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
NCT06031844: A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP

Completed
2
24
Canada, US
DFV890, Placebo
Novartis Pharmaceuticals
Coronary Heart Disease
12/24
12/24
NCT05149755: Evolut™ EXPAND TAVR II Pivotal Trial

Recruiting
N/A
650
Europe, Canada, Japan, US, RoW
Medtronic Evolut PRO+ TAVR System, or Evolut FX TAVR System, and guideline-directed management and therapy (GDMT)
Medtronic Cardiovascular
Moderate Aortic Valve Stenosis
02/26
12/34

Download Options